SCHEMBL30794643

SCHEMBL30794643

O=C(Cc1ccc(F)cc1)Nn1nc(-c2ccccc2)c2ccccc2c1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.56
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
ALOX15 P16050 1/20 0.48
ALDH1A1 P00352 5/20 0.47
RAB9A P51151 1/20 0.47
LMNA P02545 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
USP2 O75604 2/20 0.47
TSHR P16473 2/20 0.46
KDM4E B2RXH2 2/20 0.45
TP53 P04637 2/20 0.45
POLB P06746 2/20 0.45
THRB P10828 1/20 0.45
PKM P14618 1/20 0.45
BLM P54132 1/20 0.45
CTDSP1 Q9GZU7 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1790108 1.00 MAPT (0.56) MAPTMEN1KMT2AALOX15ALDH1A1
SCHEMBL1787437 0.91 ALDH1A1 (0.49) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL30795755 0.91 ALDH1A1 (0.49) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL30796353 0.90 MAPT (0.50) MAPTMEN1KMT2AALOX15ALDH1A1
SCHEMBL1787537 0.90 MAPT (0.50) MAPTMEN1KMT2AALOX15ALDH1A1
SCHEMBL1785673 0.89 MAPT (0.49) MAPTMEN1KMT2AALOX15ALDH1A1
SCHEMBL30795077 0.89 MAPT (0.49) MAPTMEN1KMT2AALOX15ALDH1A1
SCHEMBL30795705 0.88 ALDH1A1 (0.59) MAPTMEN1KMT2AALOX15ALDH1A1
SCHEMBL1788479 0.88 ALDH1A1 (0.59) MAPTMEN1KMT2AALOX15ALDH1A1
SCHEMBL30824704 0.86 CHRNA7 (0.52) MAPTMEN1KMT2AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584250-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (VG) 2025-07-16 EP disclosed
EP-4580679-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS Biohaven Therapeutics Ltd. (VG) 2025-07-09 EP disclosed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024054807-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024050389-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-07 WO disclosed